Eli Lilly and Company

INDIANAPOLIS, May 20, 2013 /PRNewswire/ -- The many health care providers working at Eli Lilly and Company (NYSE:LLY) - including doctors, nurses, and pharmacists - play a vital role in bringing new and innovative medicines to patients. From research labs to doctors' offices, these Lilly employees bring unique insights about ... read more

INDIANAPOLIS, May 14, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, underwent scheduled surgery for a dilated aorta on Monday, May 13, 2013. "Dr. Lechleiter's surgeons have advised us that surgery went as expected and ... read more

INDIANAPOLIS, May 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Phase III clinical trial results from enzastaurin's PRELUDE study, which explored the molecule as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL). The study failed to show a statistically ... read more

INDIANAPOLIS, May 6, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that John C. Lechleiter, Ph.D., chairman, president, and chief executive officer, will undergo scheduled surgery for a dilated aorta on Monday, May 13, 2013. This condition was found during unrelated testing and has been ... read more

INDIANAPOLIS, April 26, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) celebrated National Volunteer Week April 21-27 by sending off the first of 200 volunteers who will serve in impoverished communities throughout 2013. They are part of Connecting Hearts Abroad, Lilly's global employee volunteer program launched in 2011. Volunteer ... read more

INDIANAPOLIS, April 24, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has been named to the DiversityInc "Top 50 Companies for Diversity" list for the third consecutive year. DiversityInc's "Top 50 Companies for Diversity" is known as a leading assessment of diversity management globally. To make the list, participating companies ... read more

INDIANAPOLIS, April 24, 2013 /PRNewswire/ -- -- Worldwide revenue was flat as growth in key products offset lower Zyprexa revenue following patent expirations. -- Cymbalta revenue increased 19 percent while Cialis increased 11 percent. ... read more

INDIANAPOLIS, April 17, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it has acquired two investigational positron emission tomography (PET) tracers from Siemens Medical Solutions USA, Inc. The tracers are intended to image tau (or neurofibrillary) tangles in the brain, one of two ... read more

INDIANAPOLIS, April 16, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive top-line results of two additional Phase III AWARD trials for dulaglutide, an investigational, long-acting glucagon-like peptide 1 (GLP-1) receptor agonist being studied as a once-weekly treatment for type 2 diabetes. ... read more

WASHINGTON, April 10, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) unveiled data from four key molecules that represent the next generation of its oncology pipeline at the American Association for Cancer Research (AACR) Annual Meeting held in Washington, D.C. from April 6-10. The data ... read more

INDIANAPOLIS, April 3, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its financial results for the first quarter of 2013 on Wednesday, April 24, 2013. Lilly will also conduct a conference call on that day with the investment community and media to further ... read more

INDIANAPOLIS, April 2, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it is working closely with the city on a proposal to invest an additional $180 million in the company's Indianapolis-based insulin manufacturing operations. The investment is in addition to the company's November 2012 announcement of ... read more

INDIANAPOLIS, March 18, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) presented results today at the annual European Association of Urology (EAU) Congress in Milan, Italy, of a study that showed Cialis 5 mg once daily co-administered with finasteride significantly improved scores on the International Prostate Symptom Score (IPSS), ... read more

INDIANAPOLIS, March 5, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will conduct a conference call for the media and investment community to provide a pipeline update for its diabetes business on Monday, June 24, 2013. The call, which is being held in conjunction with the ... read more

INDIANAPOLIS, Feb. 20, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the Team Solutions and Solutions for Wellness program resources for individuals living with serious mental illnesses, such as bipolar disorder and schizophrenia, have been added to the Substance Abuse and ... read more

INDIANAPOLIS, Feb. 7, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that it will discontinue the Phase 3 rheumatoid arthritis (RA) program for tabalumab, an anti-BAFF (B cell activating factor) monoclonal antibody, due to lack of efficacy. The decision was not based on safety ... read more

INDIANAPOLIS, Feb. 5, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) has been named to the NAFE Top 50 Companies for Executive Women list for 2013. Compiled by the National Association for Female Executives (NAFE), the list recognizes organizations whose policies and practices encourage women's advancement ... read more

INDIANAPOLIS, Jan. 30, 2013 /PRNewswire/ -- Leading medical experts in the fields of imaging, neurology and dementia came together today to present evidence supporting the clinical utility of beta-amyloid imaging agents, such as Amyvid(TM) (Florbetapir F 18 Injection), during a public hearing held by the Centers for Medicare & Medicaid ... read more

INDIANAPOLIS, Jan. 29, 2013 /PRNewswire/ -- -- Fourth quarter revenue declined 1 percent driven by Zyprexa patent expiration, largely offset by growth in other products. -- Fourth quarter earnings per share were $0.74 (reported), or ... read more

INDIANAPOLIS, Jan. 15, 2013 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, announced today that Amyvid (Florbetapir F 18 Injection) has received marketing authorization from the European Commission as a diagnostic radiopharmaceutical indicated for Positron Emission Tomography (PET) imaging of ... read more